DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant delivery of healthcare and monetization of health data by market participants, today provided an update on the Company's pharmaceuticals-focused subsidiary Corexa Health's pharmacy division Corexa Pharmacy. Corexa Pharmacy recently achieved several qualitative and quantitative milestones that position it to be the centerpiece of Company growth in the 2nd half of 2026.

Recent Milestones

Registration with TrumpRx to be able to offer patients access to oral GLP-1 agonist drugs, such as Eli Lilly's Foundayo® and Novo Nordisk's oral Wegovy, for as little as $149 out of pocket costs. Injectable GLP-1 agonist drugs are also now available.

Availability of GLP-1 agonist companion medical food Forzet®, manufactured by Tollo Health, LLC, to complement patients' use of GLP-1 agonist drugs for the dietary management of muscle loss associated with weight loss therapies.

Launch of online store CorexaRx.com/Store.

Integration of CorexaRx.com/Store into the Health Lives Here app (via Apple App Store and Google Play) that was recently introduced at the 2026 Pro Football Hall of Fame Game initially exclusively for former NFL players allowing patients to conduct a telemedicine visit and be prescribed and/or refill a GLP-1 agonist drug as well as Forzet, and monitor health data over time while on therapy. The Health Lives Here app is expected to launch to the public in September 2026, with a staged state by state rollout beginning in North Carolina.

Availability of Tollo Health, LLC medical food Galectovid™ and dietary supplement Tollovid® targeting customers with acute and chronic viral infections.

Availability of other dietary supplements to allow customers to order their suite of nutraceuticals from Corexa Pharmacy alongside their medications.

Portfolio expansion to non-GLP-1 agonist pharmaceutical drugs in order to dispense drugs to patients prescribed GLP-1 agonist drugs, as well as medications for other conditions.

July 2026 revenue exceeded $600,000, stabilizing Corexa Pharmacy's run rate above $7 million annually as the Company prepares to benefit from the initiation of a former NFL player-led influencer campaign to drive downloads, physician visits, GLP-1 agonist drug prescriptions and sales of companion product Forzet through the Health Lives Here app, marketed together with NFL Alumni Health